Natural Killer (NK) cells are a normal component of the immune system. They are characterized by an ability to eliminate undesirable cells in the body, and to do this without requiring an adaptive response. These characteristics make NK cells an attractive proposition as allogeneic (donor-derived) treatments which can act rapidly and effectively in a patient without requiring engagement with the patient’s own immune system. This is especially desirable in pathologies where the immune system is compromised.
The MedXCell Group has uniquely employed patented technology which enables allogeneic NK cells to be “armed” permanently using monoclonal antibodies which enable the cell-killing capacity of NK cells to be directed specifically and permanently to a particular cell target in a patient. This could be a cancer cell, a virus-infected cell, or another cell type that exhibits pathological behaviour.
The MedXCell Group will first develop products in the oncology field and believes that appropriate NK treatment can offer the best combination of safety and efficacy, as well as providing a “toolbox” of therapeutic components that can be quickly and cost effectively adapted to a wide variety of conditions.